BD and Biosero Join Forces for Robotic Integration
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology company, recently announced a strategic collaboration with Biosero, a leader in laboratory automation solutions. This exciting partnership aims to enhance robotic integration with BD's flow cytometry instruments, thereby streamlining the drug discovery and development process.
A New Era of Laboratory Automation
In a significant move towards improving efficiency in laboratory workflows, both companies are looking to develop new software capabilities. The goal is to ensure BD's flow cytometer instruments seamlessly work with Biosero’s Green Button Go® software. This collaboration not only targets the development of robust software solutions but also aims to support biopharmaceutical organizations and contract research institutions with tailored research needs, making integration with robotic platforms significantly more accessible.
Transforming Traditional Laboratory Processes
Traditionally, various stages in the flow cytometry workflow for drug discovery often involve manual intervention, making the process time-consuming and less efficient. For instance, individual multiwell plates have to be manually loaded and analyzed, which can be a lengthy task. However, with the alliance between BD and Biosero, robotic integration will enable laboratories to automatically process and change tens or even hundreds of multiwell plates without requiring human assistance. This transformation in laboratory operations underscores the increasing necessity for automation.
The Importance of Automation in Biopharma
In the ever-evolving world of biopharmaceuticals, companies are increasingly relying on automation to enhance their operational efficiency. Steve Conly, worldwide president of BD Biosciences, articulated this sentiment perfectly when he stated that robotic integration is crucial for high-throughput drug screening and cell therapy manufacturing. It allows companies to scale their operations while ensuring quality and speed in their processes. By joining forces with Biosero, BD aims to empower customers to accelerate the journey of potentially life-changing therapies to market.
The Role of Flow Cytometry
Flow cytometry stands as a vital tool throughout the various stages of drug discovery and development. During the drug screening process, it enables researchers to assess the effects of potential drug candidates on individual cells within a larger population. Moreover, in the realm of cell therapy manufacturing, flow cytometry is essential for analyzing and characterizing cells at critical stages, thus ensuring the safety and efficacy of the final product.
Biosero’s Contributions to Laboratory Automation
Biosero's laboratory automation software is designed to work seamlessly across various technologies, including flow cytometers and robotic systems, creating a cohesive ecosystem that enhances productivity and reduces the likelihood of human error. As Ryan Bernhardt, CEO of Biosero, pointed out, this collaboration is a step forward in making laboratory automation accessible, adaptable, and scalable, greatly benefiting the drug discovery landscape.
Future Availability and Onward Integration
Looking ahead, the new versions of BD's flow cytometer software that are compatible with Biosero's automation solutions will be available for research use in 2025. Key instruments such as the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System will be the first to benefit from this integration. Furthermore, the BD FACSDiscover™ range of instruments is also set to be included in future integration efforts.
About BD
BD stands among the largest global medical technology enterprises. Their mission revolves around enhancing health through improved medical innovation, diagnostics, and care delivery. With over 70,000 dedicated employees, BD remains committed to supporting health care providers and researchers in their ongoing endeavors to elevate patient care and life sciences. The company actively collaborates globally to confront pressing health challenges, aiming to optimize outcomes while minimizing costs.
About Biosero, Inc.
Biosero, a member of the BICO group, focuses on developing software and automation solutions that empower researchers. Their Green Button Go® Scheduler integrates seamlessly with various laboratory technology to streamline processes, ensuring efficient operations in life sciences, biotechnology, and pharmaceutical research.
Frequently Asked Questions
What is the focus of the collaboration between BD and Biosero?
The collaboration focuses on enhancing robotic integration with BD's flow cytometry instruments to improve drug discovery and development processes.
How does robotic integration benefit laboratories?
Robotic integration allows for automation of multiwell plate handling, reducing manual workload and increasing efficiency in research workflows.
Who is BD and what role do they play in healthcare?
BD is a leading global medical technology company that develops innovative solutions to improve healthcare, diagnostics, and therapeutic delivery.
What is the significance of flow cytometry in drug discovery?
Flow cytometry enables researchers to analyze the effects of potential drugs on individual cells, thus playing a crucial role in drug screening and safety assessment.
How can I find out more about BD and Biosero?
More information can be found on the respective company websites, where they detail their products, services, and ongoing innovations.
